ATE293700T1 - Adenovirus mit glutathion peroxydate gene - Google Patents
Adenovirus mit glutathion peroxydate geneInfo
- Publication number
- ATE293700T1 ATE293700T1 AT95926429T AT95926429T ATE293700T1 AT E293700 T1 ATE293700 T1 AT E293700T1 AT 95926429 T AT95926429 T AT 95926429T AT 95926429 T AT95926429 T AT 95926429T AT E293700 T1 ATE293700 T1 AT E293700T1
- Authority
- AT
- Austria
- Prior art keywords
- adenovirus
- glutathione
- peroxydate
- genes
- relates
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title 2
- 108010024636 Glutathione Proteins 0.000 title 1
- 229960003180 glutathione Drugs 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000006587 Glutathione peroxidase Human genes 0.000 abstract 1
- 108700016172 Glutathione peroxidases Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01009—Glutathione peroxidase (1.11.1.9)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9409982A FR2723588B1 (fr) | 1994-08-12 | 1994-08-12 | Adenovirus comprenant un gene codant pour la glutathion peroxydase |
| PCT/FR1995/001002 WO1996005320A1 (fr) | 1994-08-12 | 1995-07-26 | Adenovirus comprenant un gene codant pour la glutathion peroxydase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE293700T1 true ATE293700T1 (de) | 2005-05-15 |
Family
ID=9466290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95926429T ATE293700T1 (de) | 1994-08-12 | 1995-07-26 | Adenovirus mit glutathion peroxydate gene |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20010029249A1 (de) |
| EP (1) | EP0775213B1 (de) |
| JP (1) | JPH10504193A (de) |
| AT (1) | ATE293700T1 (de) |
| AU (1) | AU710727B2 (de) |
| CA (1) | CA2197235C (de) |
| DE (1) | DE69534165T2 (de) |
| FI (1) | FI970579A (de) |
| FR (1) | FR2723588B1 (de) |
| IL (1) | IL114904A0 (de) |
| MX (1) | MX9700851A (de) |
| NO (1) | NO970282L (de) |
| WO (1) | WO1996005320A1 (de) |
| ZA (1) | ZA956678B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6814962B1 (en) * | 1994-06-02 | 2004-11-09 | Aventis Pharma S.A. | Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| US6200799B1 (en) * | 1997-06-03 | 2001-03-13 | University Of Lausanne | Somatic gene therapy to suppress secondary cataract formation following eye surgery |
| EP2278006A3 (de) | 1997-11-06 | 2011-03-02 | Novartis Vaccines and Diagnostics S.r.l. | Antigene aus Neisseria |
| JP4399112B2 (ja) | 1998-01-14 | 2010-01-13 | カイロン ソチエタ ア レスポンサビリタ リミタータ | ＮｅｉｓｓｅｒｉａＭｅｎｉｎｇｉｔｉｄｉｓ抗原 |
| EP2261351A3 (de) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Antigene und Zusammensetzungen gegen Neisseria meningitidis |
| EP2290083B1 (de) | 1999-04-30 | 2014-08-20 | Novartis Vaccines and Diagnostics S.r.l. | Konservierte Antigene aus Neisseria |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| BR0015137A (pt) | 1999-10-29 | 2003-03-25 | Chiron Spa | Peptìdeos antigênicos de neisseria |
| DK2289545T3 (en) | 2000-01-17 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Supplemented OMV vaccine against meningococcus |
| AU2002214127B2 (en) | 2000-10-27 | 2007-06-07 | J. Craig Venter Institute, Inc. | Nucleic acids and proteins from streptococcus groups A and B |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| CA2469620A1 (en) | 2001-12-12 | 2003-06-19 | Chiron Srl. | Immunisation against chlamydia trachomatis |
| US7407986B2 (en) * | 2001-12-18 | 2008-08-05 | Brassica Foundation For Chemoprotection Research, Inc. | Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| EP1736541B1 (de) | 2004-03-29 | 2013-01-23 | Galpharma Co., Ltd. | Neues modifizierte galectin-9 protein und dessen verwendung |
| ATE522541T1 (de) | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
| EP3584312A1 (de) * | 2014-06-27 | 2019-12-25 | Angiocrine Bioscience, Inc. | Nervenzellen zur expression des adenovirus e4orf1 und verfahren zur herstellung und verwendung davon |
| CN110108883A (zh) * | 2018-10-27 | 2019-08-09 | 广州呼吸健康研究院 | 用于筛选与靶治疗ards患者的msc精准医学的标志物组合 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007541A1 (en) * | 1987-04-01 | 1988-10-06 | Chiron Corporation | Polynucleotide construct encoding a polypeptide substantially similar to human glutathione peroxidase |
| US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| JPH0327289A (ja) | 1989-06-22 | 1991-02-05 | Toyo Jozo Co Ltd | 新規な血漿型グルタチオン・パーオキシダーゼ遺伝子およびその用途 |
| WO1993020195A1 (en) * | 1992-04-01 | 1993-10-14 | Fox Chase Cancer Center | Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents |
| AU7019494A (en) | 1993-05-20 | 1994-12-20 | Baylor College Of Medicine | Genetic therapy for cardiovascular disease |
| US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
| US7252989B1 (en) * | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
-
1994
- 1994-08-12 FR FR9409982A patent/FR2723588B1/fr not_active Expired - Fee Related
-
1995
- 1995-07-26 AU AU30826/95A patent/AU710727B2/en not_active Ceased
- 1995-07-26 JP JP8507057A patent/JPH10504193A/ja active Pending
- 1995-07-26 MX MX9700851A patent/MX9700851A/es unknown
- 1995-07-26 AT AT95926429T patent/ATE293700T1/de not_active IP Right Cessation
- 1995-07-26 DE DE69534165T patent/DE69534165T2/de not_active Expired - Lifetime
- 1995-07-26 US US08/776,786 patent/US20010029249A1/en not_active Abandoned
- 1995-07-26 EP EP95926429A patent/EP0775213B1/de not_active Expired - Lifetime
- 1995-07-26 CA CA2197235A patent/CA2197235C/fr not_active Expired - Fee Related
- 1995-07-26 WO PCT/FR1995/001002 patent/WO1996005320A1/fr active IP Right Grant
- 1995-08-10 ZA ZA956678A patent/ZA956678B/xx unknown
- 1995-08-10 IL IL11490495A patent/IL114904A0/xx unknown
-
1997
- 1997-01-22 NO NO970282A patent/NO970282L/no not_active Application Discontinuation
- 1997-02-11 FI FI970579A patent/FI970579A/fi not_active IP Right Cessation
-
2004
- 2004-02-02 US US10/768,635 patent/US7241591B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2723588B1 (fr) | 1996-09-20 |
| EP0775213B1 (de) | 2005-04-20 |
| CA2197235C (fr) | 2010-07-20 |
| FI970579A0 (fi) | 1997-02-11 |
| MX9700851A (es) | 1997-04-30 |
| CA2197235A1 (fr) | 1996-02-22 |
| DE69534165T2 (de) | 2006-03-09 |
| NO970282D0 (no) | 1997-01-22 |
| US20010029249A1 (en) | 2001-10-11 |
| DE69534165D1 (de) | 2005-05-25 |
| ZA956678B (en) | 1996-03-20 |
| FR2723588A1 (fr) | 1996-02-16 |
| US7241591B2 (en) | 2007-07-10 |
| WO1996005320A1 (fr) | 1996-02-22 |
| IL114904A0 (en) | 1995-12-08 |
| FI970579A (fi) | 1997-02-11 |
| EP0775213A1 (de) | 1997-05-28 |
| US20040175363A1 (en) | 2004-09-09 |
| AU3082695A (en) | 1996-03-07 |
| AU710727B2 (en) | 1999-09-30 |
| NO970282L (no) | 1997-01-22 |
| JPH10504193A (ja) | 1998-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE293700T1 (de) | Adenovirus mit glutathion peroxydate gene | |
| UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
| NO962791L (no) | Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse | |
| ATE365808T1 (de) | Transportproteine und deren verwendungen | |
| DK0720482T3 (da) | Prosaposin og cytokin-afledte peptider som terapeutiske midler | |
| MX9606327A (es) | Adenovirus que comprende un gen que codifica para un superoxido dismutasa. | |
| BR9405507A (pt) | Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica | |
| CY1109367T1 (el) | Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα | |
| IL138665A0 (en) | Peptide factor | |
| ES2168457T3 (es) | Composiciones farmaceuticas que comprenden una superoxido dismutasa. | |
| BG103968A (en) | Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity | |
| FI940375A (fi) | Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa | |
| TR199802648A2 (xx) | Gen tedavisi i�in n�klein asit yap�lar�. | |
| IT1270618B (it) | Proteine ad attivita' antitumorale | |
| CA2278808A1 (en) | Methods for cultivating cells and propagating viruses | |
| TR199901190T2 (xx) | Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler. | |
| NO20000990L (no) | Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta> | |
| BR9713981A (pt) | Vetor recombinante para a expressão induzìvel e hepatoespecìfica de uma molécula, adenovìrus recombinante, vetor adenoviral, variante do promotor do gene da apolipoproteìna aii humana, célula, composição farmacêutica, processo para produção de uma proteìna recombinante, e, utilização de um adenovìrus | |
| MX9700298A (es) | Adenovirus que comprende un gen que codifica para una no sintasa. | |
| DE69737992D1 (de) | Genetische abschaffung und austausch | |
| ID23184A (id) | Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi | |
| DE69718047D1 (de) | Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose | |
| IT1294967B1 (it) | Composizione immunogenica da tlp | |
| BR9407357A (pt) | Novos tripeptideos utilizáveis em terapia cns e imune | |
| TR199700842T1 (xx) | �nsan DNase I Varyantlar�. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |